The company has signed an agreement with MTF Biologics, the world’s largest tissue bank, to extend and strengthen its US product offering.
The agreement will give the company US rights to two forms of bone graft materials comprised of 100% demineralized bone matrix (DBM), which offer improved osteoinductivity when compared to many other DBM products according to Bonesupport. These products, which are both osteoinductive and osteoconductive, complement CERAMENT BVF (osteoconductive) and the products gained from the company’s recent strategic agreement with Collagen Matrix Inc. (osteoinductive and osteogenic)
“Today’s deal with MTF Biologics is a further important step in creating the broad and complementary US product offering that will address the needs of orthopedic surgeons managing bone voids. We are pleased that MTF Biologics, the world’s leading tissue bank, has chosen to partner with Bonesupport, and we look forward to marketing products based on their high-quality demineralized bone matrix. With our expanded product portfolio and new broad US distribution channel, that we are on track to have in place in late October, we are well placed to significantly improve our competitive position and rapidly grow sales ahead of the planned US launch of CERAMENT G in 2021,” said Emil Billbäck, CEO of Bonesupport.
Bonesupport plans to launch the products supplied by MTF Biologics under the Bonesupport brand name and through its own US distribution network.
TF Biologics is a non-profit service organization dedicated to providing clinically sound, safe allograft tissue. MTF Biologics is comprised of a national consortium of academic medical institutions, organ procurement organizations and tissue recovery organizations. It is based in Edison, NJ, USA.
